Quantum Biopharma (QNTM) Amortization (2019 - 2026)

Quantum Biopharma's Amortization history runs 8 years deep, the most recent figure standing at -$13.8 million for Q1 2026.

• In Q1 2026, Amortization fell 232.96% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at -$32.3 million (down 412.08% YoY), while the FY2024 annual figure was $12.1 million, down 6.63% from the prior year.
• Amortization came in at -$13.8 million for Q1 2026 at Quantum Biopharma, down from -$4.7 million in the prior quarter.
• In the past five years, Amortization ranged from a high of $55.7 million in Q1 2022 to a low of -$13.8 million in Q1 2026.
• A 5-year average of $13.6 million and a median of $11.2 million in 2024 frame the typical range for Amortization.
• Across the five-year window, Amortization surged 594.61% in 2025 and slumped 232.96% in 2026, its largest moves.
• Quantum Biopharma's Amortization stood at $38.4 million in 2022, then plunged by 66.39% to $12.9 million in 2023, then decreased by 6.63% to $12.1 million in 2024, then tumbled by 139.39% to -$4.7 million in 2025, then slumped by 189.7% to -$13.8 million in 2026.
• According to Business Quant data, Amortization over the past three periods registered -$13.8 million, -$4.7 million, and -$9.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison